Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC
Status:
Not yet recruiting
Trial end date:
2024-08-19
Target enrollment:
Participant gender:
Summary
To explore the efficiency and safety of TP chemotherapy, tislelizumab, combined with afatinib
as a new neoadjuvant treatment regimen for patients with resectable HNSCC.